Biological emergency preparedness

01Overview and value chain#

Markers EC: CEPI 100 Days Mission rapid-response framework + EU HERA medical-countermeasure preparedness mandate | OECD: Bioeconomy policy & governance | Regulator: FDA (USA), EMA (EU)

Biological emergency preparedness builds and exercises the institutional capacity to detect, respond to, and rapidly counter a biological outbreak before it becomes an uncontrolled pandemic. The field spans four distinct activities: rapid vaccine-response frameworks that compress the time from pathogen identification to an authorized countermeasure toward a 100-day target, pandemic exercises and simulations that stress-test national and multilateral response plans under realistic scenario conditions, biosecurity policy work that closes practical gaps such as unscreened DNA-synthesis orders or ungoverned AI biodesign tools, and dedicated government authorities that reserve manufacturing capacity and stockpile medical countermeasures ahead of a declared emergency. A World Health Organization pandemic simulation in 2026 brought together 26 countries over two days specifically to test whether existing plans hold up under pressure, while the EU’s dedicated health-emergency authority ran parallel tenders in 2026 for a filovirus investigational-vaccine reserve and personal protective-equipment manufacturing-capacity reservation. The category is distinct from vaccine and medical-countermeasure manufacturing itself and from diagnostic-platform development covered elsewhere on this platform: biological emergency preparedness is specifically the governance, exercise, and readiness-financing layer that decides how fast and how well a response actually happens once a biological threat is identified.

The key directions of biological emergency preparedness are:

Rapid vaccine-response frameworks: coordinated funding and manufacturing frameworks compress the pathogen-to-authorized-vaccine timeline toward a 100-day target, restructuring clinical-trial and manufacturing sequencing that traditionally took years into a compressed emergency-response pathway.
Pandemic exercise and simulation programs: tabletop and full-scale exercises, including multi-country simulations run by international health bodies, test national and multilateral response plans under realistic scenario pressure before a real outbreak occurs.
Biosecurity policy and governance: advocacy and analysis close specific, practical readiness gaps — mandatory screening of DNA-synthesis orders, managed access controls to prevent AI tools from being used to design dangerous pathogens, and reducing state-level biological-weapons risks.
Medical-countermeasure stockpiling and capacity reservation: dedicated government authorities reserve manufacturing capacity in advance and stockpile vaccines, therapeutics, and personal protective equipment against a declared biological emergency.

Sectoral value chain#

[Threat/pathogen identification] ──> [Rapid-response framework activation] ──> [Manufacturing/stockpile mobilization]
                                                                                        │
                                                                              (exercise-tested readiness)
                                                                                        │
                                                                                        ▼
[Emergency response deployment] <─── [Policy/regulatory authorization] <─── [Countermeasure development]

Fig. 1— Sectoral value chain

Value chain levels#

Level	Description	Key inputs/outputs
Threat/pathogen identification	An emerging biological threat is identified, either through surveillance or a declared outbreak.	In: surveillance data, outbreak report. Out: identified threat/pathogen.
Rapid-response framework activation	A coordinated response framework is activated, sequencing funding, clinical-trial, and manufacturing steps toward a compressed timeline.	In: identified threat, response framework. Out: activated response plan.
Countermeasure development	Vaccine, therapeutic, or diagnostic countermeasures are developed under the compressed emergency-response pathway.	In: activated response plan, R&D capacity. Out: candidate countermeasure.
Policy/regulatory authorization	Regulators grant emergency-use or accelerated authorization for the countermeasure.	In: candidate countermeasure, safety/efficacy data. Out: authorized countermeasure.
Manufacturing/stockpile mobilization	Reserved manufacturing capacity and stockpiled inventory are mobilized to produce and distribute the authorized countermeasure at scale.	In: authorized countermeasure, reserved capacity. Out: distributed countermeasure supply.
Emergency response deployment	The countermeasure and response plan are deployed against the biological emergency, informed by prior exercise and simulation testing.	In: distributed supply, tested response plan. Out: deployed emergency response.

Table 1— Value chain levels

Cross-cutting technologies of the sector:

Rapid vaccine-response frameworks: coordinated funding and manufacturing sequencing compress the pathogen-to-authorized-vaccine timeline toward a 100-day emergency-response target.
Pandemic exercise and simulation programs: multi-country tabletop and full-scale exercises test whether existing national and multilateral response plans function under realistic pressure before a real emergency occurs.
Medical-countermeasure stockpiling: advance reservation of manufacturing capacity and stockpiled inventory for vaccines, therapeutics, and protective equipment ahead of a declared biological emergency.

02US#

The US hosts a biosecurity policy organization closing practical readiness gaps and a research institute developing and running pandemic exercise scenarios.

biosecurity policy advocacy, pandemic exercise scenario design#

Nuclear Threat Initiative | bio: advocates for mandatory screening of DNA-synthesis orders to close a biosecurity gap, publishes on managed-access controls to prevent AI tools from being used to design dangerous pathogens, and works to reduce state-level biological-weapons risks.
Johns Hopkins Center for Health Security: develops pandemic exercise scenarios used in public-health communications training, and its work informs multi-country simulation exercises such as the World Health Organization’s 2026 readiness test involving 26 countries.

03CN#

No China-headquartered biological-emergency-preparedness organization cleared this screening round with confirmed, on-domain evidence.

screening limitation#

Screening note: a candidate China public-health emergency response center was probed twice with different search framings and did not return confirming, organization-specific evidence either time — not asserted as absent, only as unconfirmed this round.

04EU#

The EU hosts a Norway-headquartered global vaccine-preparedness coalition and the European Commission’s dedicated health-emergency preparedness and response authority.

rapid vaccine-response coordination, medical-countermeasure stockpiling#

CEPI (Coalition for Epidemic Preparedness Innovations): leads the 100 Days Mission, a coordinated framework to compress the pathogen-to-authorized-vaccine timeline, publishing rapid-response manufacturing frameworks and emergency clinical- research principles with academic and industry partners.
HERA (EU Health Emergency Preparedness and Response Authority): reserves manufacturing capacity for personal protective equipment through its EU FAB+ pilot and runs EU4Health tenders for a filovirus investigational-vaccine reserve covering Marburg and Sudan Ebola virus disease.

05Leading companies and research institutes#

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
CEPI	🇳🇴 Norway	100 Days Mission rapid vaccine-response framework	Compresses pathogen-to-vaccine timeline via coordinated funding/manufacturing	Nonprofit coalition
Nuclear Threat Initiative \| bio	🇺🇸 USA	Biosecurity policy advocacy and analysis	DNA-synthesis screening advocacy, AI biodesign governance	Nonprofit institute
Johns Hopkins Center for Health Security	🇺🇸 USA	Pandemic exercise scenario design	Informs multi-country readiness simulations	Research institute
HERA	🇪🇺 EU	Medical-countermeasure stockpiling and capacity reservation	EU FAB+ PPE pilot, filovirus vaccine reserve tenders	Government authority

Table 2— Leading companies and research institutes

06Tech stack and innovations#

The stack layers compressed vaccine-development frameworks, exercise-based readiness testing, and advance-capacity stockpiling on a common emergency-preparedness backbone.

Compressed rapid-response development frameworks:
- Coordinated funding and manufacturing sequencing restructure the traditional multi-year vaccine-development timeline toward a 100-day emergency-response target, resequencing clinical-trial and manufacturing steps that traditionally ran sequentially into overlapping, pre-planned phases.
- This capability is designed to activate immediately upon a declared threat rather than being assembled reactively after an outbreak begins.
Multi-country exercise and simulation design:
- Scenario-based exercises, including multi-country simulations run by international health bodies, test whether existing response plans function under realistic pressure, revealing coordination gaps before a real emergency exposes them.
- Exercise findings directly inform revisions to national and multilateral response doctrine, closing the loop between simulated and real-world readiness.
Advance manufacturing-capacity reservation and stockpiling:
- Dedicated government authorities reserve manufacturing capacity and stockpile vaccines, therapeutics, and protective equipment ahead of a declared emergency, avoiding the capacity-scramble that characterized early-pandemic response shortfalls.
- This capability pairs with targeted vaccine reserves for specific high-consequence pathogens, rather than relying solely on general-purpose manufacturing surge capacity.

07Value chains and production pipelines#

Industrial pipeline of biological emergency preparedness (CEPI 100 Days Mission / EU HERA mandate)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Threat/pathogen         │ ───> │ 2. Rapid-response           │
│    identification           │      │    framework activation     │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Policy/regulatory       │ <─── │ 3. Countermeasure            │
│    authorization            │      │    development               │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Manufacturing/stockpile │ ───> │ 6. Emergency response        │
│    mobilization             │      │    deployment                │
└───────────────────────────┘      └───────────────────────────┘

Fig. 2— Industrial pipeline of biological emergency preparedness (CEPI 100 Days Mission / EU HERA mandate)

Stage 1: Threat/pathogen identification

An emerging biological threat is identified, either through surveillance or a declared outbreak.

Stage 2: Rapid-response framework activation

A coordinated response framework is activated, sequencing funding, clinical-trial, and manufacturing steps toward a compressed timeline.

Stage 3: Countermeasure development

Vaccine, therapeutic, or diagnostic countermeasures are developed under the compressed emergency-response pathway.

Stage 4: Policy/regulatory authorization

Regulators grant emergency-use or accelerated authorization for the countermeasure.

Stage 5: Manufacturing/stockpile mobilization

Reserved manufacturing capacity and stockpiled inventory are mobilized to produce and distribute the authorized countermeasure at scale.

Stage 6: Emergency response deployment

The countermeasure and response plan are deployed against the biological emergency, informed by prior exercise and simulation testing.

Supplier	Price	Lead time	Certificates	Risk	Confidence
CEPI	custom	on request	Government program	Low	HIGH
Nuclear Threat Initiative \| bio	custom	on request	Research institute	Low	MEDIUM
Johns Hopkins Center for Health Security	custom	on request	Research institute	Low	HIGH
HERA	custom	on request	Government program	Low	HIGH

AI Recommendation

CEPI isn’t a vendor to contract directly; it’s the nonprofit coalition to reference when scoping a rapid vaccine-response strategy, particularly its 100 Days Mission framework for compressing pathogen-to-vaccine timelines. Nuclear Threat Initiative | bio is a policy and advocacy reference, not a service provider — useful for orienting biosecurity gaps like DNA-synthesis screening rather than for a direct engagement. Johns Hopkins Center for Health Security is the reference point for pandemic exercise and simulation design methodology, informing programs like the WHO’s multi-country readiness tests. HERA is the EU’s own government authority for medical-countermeasure stockpiling and manufacturing-capacity reservation — a policy and procurement counterpart, not a commercial vendor.

Key directions: rapid vaccine-response frameworks, pandemic exercise and simulation programs, biosecurity policy and governance, and medical-countermeasure stockpiling and capacity reservation.

Regulatory: biological emergency preparedness sits within FDA emergency-use authorization pathways in the US and the EU’s HERA-coordinated medical-countermeasure preparedness mandate.

Companies not in table: a candidate China public-health emergency response center was checked twice with different search framings and returned no organization-specific confirming evidence either time.